Tobira is focused on developing and commercializing innovative therapeutics to treat liver disease, human immunodeficiency virus, or HIV-1, fibrosis and inflammation. Its lead product candidate, cenicriviroc, or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. Tobira’s management team has extensive experience in developing and commercializing therapeutics for liver disease and HIV-1. The lead indication for CVC is non-alcoholic steatohepatitis, or NASH, for which Tobira plans to begin a Phase 2 clinical trial in the second half of 2014. The company believes there are no other product candidates in development for NASH that target the immuno-inflammatory pathways responsible for fibrosis. CVC also is Phase 3-ready in HIV-1 infection with potential as the backbone in a fixed-dose combination therapy. CVC is a once-daily pill with a safety and tolerability profile that has been established to date in 550 subjects dosed in completed Phase 1 and Phase 2 trials, including 115 HIV-1 infected subjects on treatment for up to 48 weeks.
View Top Employees from Tobira TherapeuticsWebsite | http://www.tobiratherapeutics.com |
Ticker | NASDAQ:TBRA |
Revenue | $4 million |
Employees | 5 (5 on RocketReach) |
Founded | 2007 |
Address | 701 Gateway Blvd. Suite 300, South San Francisco, California 94080, US |
Phone | (650) 741-6625 |
Technologies |
Zoom,
Cisco WebEx,
Cisco IronPort
+2 more
(view full list)
|
Industry | Biotechnology, Drug Manufacturing & Research, Developing innovative therapeutics to treat liver disease, HIV, , Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Therapeutics |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325412 Companies, NAICS Code 32541 Companies |
Looking for a particular Tobira Therapeutics employee's phone or email?
The Tobira Therapeutics annual revenue was $4 million in 2024.
Cliff Sachs is the Director, Quality Assurance of Tobira Therapeutics.
5 people are employed at Tobira Therapeutics.
Tobira Therapeutics is based in South San Francisco, California.
The NAICS codes for Tobira Therapeutics are [325, 3254, 32, 325412, 32541].
The SIC codes for Tobira Therapeutics are [283, 28].